Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.